Journal ArticleDOI
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia
Gabriel Etienne,Joelle Guilhot,Delphine Rea,Françoise Rigal-Huguet,Franck E. Nicolini,Aude Charbonnier,Agnès Guerci-Bresler,Laurence Legros,Bruno Varet,Martine Gardembas,Viviane Dubruille,Michel Tulliez,Marie-Pierre Noel,Jean-Christophe Ianotto,Bruno Villemagne,Martin Carre,François Guilhot,Philippe Rousselot,Francois-Xavier Mahon +18 more
Reads0
Chats0
TLDR
With a median follow-up of more than 6 years after treatment discontinuation, the STIM1 study demonstrates that IM can safely be discontinued in patients with a sustained deep molecular response with no late MR.Abstract:
PurposeImatinib (IM) can safely be discontinued in patients with chronic myeloid leukemia (CML) who have had undetectable minimal residual disease (UMRD) for at least 2 years. We report the final results of the Stop Imatinib (STIM1) study with a long follow-up.Patients and MethodsIM was prospectively discontinued in 100 patients with CML with UMRD sustained for at least 2 years. Molecular recurrence (MR) was defined as positivity of BCR-ABL transcript in a quantitative reverse transcriptase polymerase chain reaction assay confirmed by a second analysis point that indicated an increase of one log in relation to the first analysis point at two successive assessments or loss of major molecular response at one point.ResultsThe median molecular follow-up after treatment discontinuation was 77 months (range, 9 to 95 months). Sixty-one patients lost UMRD after a median of 2.5 months (range, 1 to 22 months), and one patient died with UMRD at 10 months. Molecular recurrence-free survival was 43% (95% CI, 33% to 52...read more
Citations
More filters
Journal ArticleDOI
Cancer treatment and survivorship statistics, 2019
Kimberly D. Miller,Leticia Nogueira,Angela B. Mariotto,Julia H. Rowland,K. Robin Yabroff,Catherine M. Alfano,Ahmedin Jemal,Joan L. Kramer,Rebecca L. Siegel +8 more
TL;DR: Estimating cancer prevalence in the United States using incidence and survival data from the Surveillance, Epidemiology, and End Results cancer registries; vital statistics from the Centers for Disease Control and Prevention's National Center for Health Statistics; and population projections from the US Census Bureau is presented.
Journal ArticleDOI
Clinical practice guidelines in oncology
William J. Gradishar,Benjamin O. Anderson,Ron Balassanian,Sarah L. Blair,Harold J. Burstein,Amy E. Cyr,Anthony D. Elias,William B. Farrar,Andres Forero,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Janice A. Lyons,P. Kelly Marcom,Ingrid A. Mayer,Beryl McCormick,Meena S. Moran,Ruth O'Regan,Sameer A. Patel,Lori J. Pierce,Elizabeth C. Reed,Kilian E. Salerno,Lee S. Schwartzberg,Amy Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,George Somlo,Melinda L. Telli,John H. Ward,Rashmi Kumar,Dorothy A. Shead +32 more
TL;DR: This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
Journal ArticleDOI
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Andreas Hochhaus,Michele Baccarani,Richard T. Silver,Charles A. Schiffer,Jane F. Apperley,Francisco Cervantes,Richard E. Clark,Jorge E. Cortes,Michael W. Deininger,François Guilhot,Henrik Hjorth-Hansen,Timothy P. Hughes,Jeroen Janssen,Hagop M. Kantarjian,Dong-Wook Kim,Richard A. Larson,Jeffrey H. Lipton,Francois-Xavier Mahon,Jiří Mayer,Franck E. Nicolini,Dietger Niederwieser,Fabrizio Pane,Jerald P. Radich,Delphine Rea,Johan Richter,Gianantonio Rosti,Philippe Rousselot,Giuseppe Saglio,Susanne Saußele,Simona Soverini,Juan Luis Steegmann,Anna G. Turkina,Andrey Zaritskey,Ruediger Hehlmann +33 more
TL;DR: An expert panel to critically evaluate and update the evidence to achieve goals to achieve a stable deep molecular response (DMR) and discontinuing medication for treatment-free remission (TFR) in chronic myeloid leukemia.
Journal ArticleDOI
Cancer treatment and survivorship statistics, 2022
Kimberly D. Miller,Leticia Nogueira,Theresa P Devasia,Angela B. Mariotto,K. Robin Yabroff,Ahmedin Jemal,Joan L. Kramer,Rebecca L. Siegel +7 more
TL;DR: Estimation of cancer prevalence in the United States using incidence and survival data from the Surveillance, Epidemiology, and End Results cancer registries, vital statistics from the Centers for Disease Control and Prevention’s National Center for Health Statistics, and population projections from the US Census Bureau finds that more than 18 million Americans with a history of cancer were alive on January 1, 2022.
Journal ArticleDOI
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
Susanne Saussele,Johan Richter,Joelle Guilhot,Franz Gruber,Henrik Hjorth-Hansen,Antonio Almeida,Jeroen Janssen,Jiri Mayer,Perttu Koskenvesa,Panayiotis Panayiotidis,Ulla Olsson-Strömberg,Joaquin Martinez-Lopez,Philippe Rousselot,Hanne Vestergaard,Hans Ehrencrona,Veli Kairisto,Katerina Machova Polakova,Martin Müller,Satu Mustjoki,Marc G. Berger,Alice Fabarius,Wolf-Karsten Hofmann,Andreas Hochhaus,Markus Pfirrmann,Francois-Xavier Mahon,Gert J. Ossenkoppele,Maria Pagoni,Stina Söderlund,Martine Escoffre-Barbe,Gabriel Etienne,Jolanta Dengler,Françoise Huguet,Nikolas von Bubnoff,Hana Klamova,Edgar Faber,François Guilhot,Kourosh Lotfi,Delphine Rea,Tim H. Brümmendorf,Gorgine E. de Greef,Leif Stenke,Franck E. Nicolini,Laurence Legros,Andreas Burchert,Jaroslava Voglová,Aude Charbonnier,Emmanuel Gyan,Volker Kunzmann,Peter E. Westerweel +48 more
TL;DR: In this paper, a prospective, non-randomised trial was conducted at 61 European centres in 11 countries to investigate the impact of stopping TKI therapy on the survival of patients with chronic myeloid leukaemia.
References
More filters
Journal ArticleDOI
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker,François Guilhot,Stephen G. O'Brien,Insa Gathmann,Hagop M. Kantarjian,Norbert Gattermann,Michael W. Deininger,Richard T. Silver,John M. Goldman,Richard Stone,Francisco Cervantes,Andreas Hochhaus,Bayard L. Powell,Janice Gabrilove,Philippe Rousselot,Josy Reiffers,Jan J. Cornelissen,Timothy P. Hughes,Hermine Agis,Thea Kolsen Fischer,Gregor Verhoef,John D. Shepherd,Giuseppe Saglio,Alois Gratwohl,Johan Lanng Nielsen,Jerald P. Radich,Bengt Simonsson,Kerry Taylor,Michele Baccarani,Charlene So,Laurie Letvak,Richard A. Larson +31 more
TL;DR: After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients.
Journal ArticleDOI
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon,Delphine Rea,Joelle Guilhot,François Guilhot,Françoise Huguet,Franck E. Nicolini,Laurence Legros,Aude Charbonnier,Agnès Guerci,Bruno Varet,Gabriel Etienne,Josy Reiffers,Philippe Rousselot +12 more
TL;DR: Imatinib discontinuation in this setting yields promising results for molecular relapse-free survival, raising the possibility that, at least in some patients, CML might be cured with tyrosine kinase inhibitors.
Journal ArticleDOI
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.
Andreas Hochhaus,Stephen G. O'Brien,François Guilhot,B. J. Druker,Susan Branford,Letizia Foroni,JohnM. Goldman,Martin C. Müller,Jerald P. Radich,Marc Rudoltz,Manisha Mone,Insa Gathmann,Timothy P. Hughes,Richard A. Larson +13 more
TL;DR: During the sixth year of study treatment, there were no reports of disease progression to accelerated phase (AP) or blast crisis (BC), and the toxicity profile was unchanged.
Journal ArticleDOI
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M. Ross,Susan Branford,John F. Seymour,Anthony P. Schwarer,Christopher Arthur,David T Yeung,David T Yeung,Phuong Dang,Jarrad M. Goyne,Cassandra Slader,Robin Filshie,Anthony K. Mills,Junia V. Melo,Junia V. Melo,Deborah L. White,Deborah L. White,Andrew Grigg,Timothy P. Hughes,Timothy P. Hughes +18 more
TL;DR: The results confirm the safety and efficacy of a trial of imatinib withdrawal in stable UMRD with frequent, sensitive molecular monitoring and early rescue of molecular relapse, and show persistence of the original CML clone in all patients with stable U MRD, even several years after imatinIB withdrawal.
Journal ArticleDOI
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
Andreas Hochhaus,Giuseppe Saglio,Timothy P. Hughes,Richard A. Larson,Dong-Kee Kim,Surapol Issaragrisil,P. le Coutre,Gabriel Etienne,Pedro Enrique Dorlhiac-Llacer,Richard E. Clark,Ian W. Flinn,Hirohisa Nakamae,Breanne Donohue,Weiping Deng,Darshan Dalal,Hans D. Menssen,Hagop M. Kantarjian +16 more
TL;DR: Long-term results support the positive benefit-risk profile of frontline nilotinib 300 mg twice daily in patients with CML-CP, and few deaths in any arm were associated with CVEs, infections or pulmonary diseases.
Related Papers (5)
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M. Ross,Susan Branford,John F. Seymour,Anthony P. Schwarer,Christopher Arthur,David T Yeung,David T Yeung,Phuong Dang,Jarrad M. Goyne,Cassandra Slader,Robin Filshie,Anthony K. Mills,Junia V. Melo,Junia V. Melo,Deborah L. White,Deborah L. White,Andrew Grigg,Timothy P. Hughes,Timothy P. Hughes +18 more
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
Susanne Saussele,Johan Richter,Joelle Guilhot,Franz Gruber,Henrik Hjorth-Hansen,Antonio Almeida,Jeroen Janssen,Jiri Mayer,Perttu Koskenvesa,Panayiotis Panayiotidis,Ulla Olsson-Strömberg,Joaquin Martinez-Lopez,Philippe Rousselot,Hanne Vestergaard,Hans Ehrencrona,Veli Kairisto,Katerina Machova Polakova,Martin Müller,Satu Mustjoki,Marc G. Berger,Alice Fabarius,Wolf-Karsten Hofmann,Andreas Hochhaus,Markus Pfirrmann,Francois-Xavier Mahon,Gert J. Ossenkoppele,Maria Pagoni,Stina Söderlund,Martine Escoffre-Barbe,Gabriel Etienne,Jolanta Dengler,Françoise Huguet,Nikolas von Bubnoff,Hana Klamova,Edgar Faber,François Guilhot,Kourosh Lotfi,Delphine Rea,Tim H. Brümmendorf,Gorgine E. de Greef,Leif Stenke,Franck E. Nicolini,Laurence Legros,Andreas Burchert,Jaroslava Voglová,Aude Charbonnier,Emmanuel Gyan,Volker Kunzmann,Peter E. Westerweel +48 more
Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
Philippe Rousselot,Aude Charbonnier,Pascale Cony-Makhoul,Philippe Agape,Franck E. Nicolini,Bruno Varet,Martine Gardembas,Gabriel Etienne,Delphine Rea,Lydia Roy,Martine Escoffre-Barbe,Agnès Guerci-Bresler,Michel Tulliez,Stéphane Prost,Marc Spentchian,Jean Michel Cayuela,Josy Reiffers,Jean-Claude Chomel,Ali G. Turhan,Joelle Guilhot,François Guilhot,Francois-Xavier Mahon +21 more
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani,Michael W. Deininger,Gianantonio Rosti,Andreas Hochhaus,Simona Soverini,Jane F. Apperley,Francisco Cervantes,Richard E. Clark,Jorge E. Cortes,François Guilhot,Henrik Hjorth-Hansen,Timothy P. Hughes,Hagop M. Kantarjian,Dong-Wook Kim,Richard A. Larson,Jeffrey H. Lipton,François Xavier Mahon,Giovanni Martinelli,Jiri Mayer,Martin C. Müller,Dietger Niederwieser,Fabrizio Pane,Jerald P. Radich,Philippe Rousselot,Giuseppe Saglio,Susanne Saußele,Charles A. Schiffer,Richard T. Silver,Bengt Simonsson,Juan Luis Steegmann,John M. Goldman,Rüdiger Hehlmann +31 more